The 15-subject enrollment level approved for the company-sponsored clinical study has been met. The final subject is expected to complete the multi-day protocol in approximately six weeks. The enrollment limit was reached in just 9 weeks, providing another indication of the tremendous number of women afflicted with OAB and the urgent need for new and innovative therapies for their symptoms of overactive bladder.
